Prostate cancer (PCa) is the most common non-cutaneous cancer among men and the second leading cause of male cancer deaths in the United States. With no effective cure for advanced disease, the survival rates of castration-resistant disease and metastatic disease remains poor. Treatment via hormonal manipulation, immunotherapy, and chemotherapy remain marginally effective, indicating the need for novel treatment strategies. Cytoreductive prostatectomy (CRP) has grown as a treatment modality for metastatic castration resistant prostate cancer (mCRPC) and an emerging body of literature has demonstrated its survival benefits. In this review, we hope to further explore immunologic changes after CRP and the resultant effects on oncologic outcomes. Conclusively, the data and technical considerations of CRS evolve, CRS may continue to expand treat various type of metastatic cancer. Still, there are little reports about immunological changed after CRP. However, based on technical improvement, CRP and combinational immunotherapy are developing treatments of metastatic disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526355 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Stereotactic Body Therapy for Urologic Cancers-What the Urologist Needs to Know.
Life (Basel)
December 2024
Department of Surgery, Peter MacCallum Cancer Centre, The University of Melbourne, Parkville, VIC 3052, Australia.
Background: stereotactic ablative body radiotherapy (SABR) is a disruptive radiation therapy technique which is increasingly used for the treatment of urologic cancers. The aim of this narrative review is to provide an overview on the current landscape of SABR in urologic cancers and highlight advancements on the horizon.
Methods: a narrative review of the contemporary role of SABR in urologic cancers is conducted.
Prostatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials.
Curr Opin Urol
November 2024
Department of Urology.
Article Synopsis
- Oligometastatic prostate cancer (OMPCa) is an intermediate stage of cancer between localized and widespread disease, traditionally treated with androgen deprivation therapy (ADT) but now also considered for local therapies like cytoreductive prostatectomy (CRP) and radiotherapy.
- Recent studies suggest that CRP may be beneficial for some OMPCa patients, and ongoing trials are exploring its safety and effectiveness, alongside findings supporting the use of radiotherapy and ADT.
- There is still limited evidence for focal therapies and cryotherapy, highlighting the need for more clinical trials to better understand treatment options and suitability for patients with OMPCa.
A case report on the atypical metastatic pathway of prostate cancer to the kidney and stomach.
Urol Case Rep
September 2024
Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
Prostate cancer rarely metastasizes to the stomach and kidneys. We report a 73-year-old male with such spread, highlighting significant clinical challenges. Initially diagnosed via biopsy and imaging, he received hormone therapy and cytoreductive radical prostatectomy.
View Article and Find Full Text PDFASO Author Reflections: It Does Not Matter Whether Radical Prostatectomy is Performed in High-Risk Localized Disease or at the Oligometastatic Stage.
Ann Surg Oncol
November 2024
Department of Urology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
Radical prostatectomy (RP) alone has traditionally been considered insufficient for patients with high-risk localized prostate cancer (HRPC) owing to the frequent need for adjuvant salvage radiotherapy or androgen deprivation therapy (ADT) following surgery. Previously, systemic therapy, such as ADT, was the standard treatment for metastatic prostate cancer (PC) patients; RP was not considered viable for these patients. However, since 2015, there has been a recognition that metastatic PC patients can be categorized based on the extent of their metastases, leading to the consideration of RP for some metastatic cases.
View Article and Find Full Text PDFEvidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review.
Memo
February 2024
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Introduction: Metastatic hormone-sensitive prostate cancer (mHSPC) displays both simultaneous and sequential patterns of metastasis, emphasizing a comprehensive treatment approach that integrates both local therapy and systemic treatment strategies. The increasing use of molecular imaging has led to a rise in mHSPC diagnoses, underscoring the importance of identifying the right patient population and effective treatment concepts for this disease state.
Results: Two prospective trials, HORRAD and STAMP EDE, investigated prostate radiotherapy (RT) for mHSPC; however, they did not show an overall survival (OS) benefit in the unselected cohort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!